Outline of JUA clinical guidelines for benign prostatic hyperplasia

Abstract

Abstract:The Japanese Urological Association has developed Clinical Guidelines for Benign Prostatic Hyperplasia (BPH) for men with suspected BPH, which have been abridged and translated into English. This article is a shortened version of the English translation. The Guidelines were formulated on the basis of evidence retrieved from the PubMed database between 1995 and 2009, as well as other relevant sources. The target patients of these Guidelines are men with suspected BPH, and the target users are urologists. A mandatory assessment should include a medical history, a physical examination, the completion of symptom and quality of life questionnaires, urinalysis, prostate ultrasonography, measurement of serum prostate specific antigen and postvoid residual urine, and an uroflowmetry. Optional tests include a bladder diary, the measurement of serum creatinine, and upper urinary tract ultrasonography. Care should be taken to not overlook coexisting diseases such as an infection or malignancy that may obscure the diagnosis. Treatment should consist of conservative therapy or the use of medications such as a 1-adrenoceptor antagonists, or both. The use of 5a-reductase inhibitors or anticholinergic agents should be considered in patients with an enlarged prostate (>30 mL) or overactive bladder symptoms (overactive bladder symptom score Ն6), respectively. Surgical intervention is indicated when nonsurgical treatments fail to provide sufficient symptomatic relief and bladder outlet obstruction is highly suspected.

Comparison of outpatient versus inpatient transurethral prostate resection for benign prostatic hyperplasia: Comparative, prospective bi-center study.

“…8 Until recently, TURP has been considered the gold standard for minimally invasive treatment for BPH when prostate volumes range from 30 to 80 mL. 9 However, less invasive operative modalities have been developed to treat BPH to reduce TURP-related morbidity, and to maintain efficacy and minimize risk associated with BPH treatment. There are currently many alternatives, including microwave thermotherapy, radiofrequency ablation, bipolar resection or vaporization plus various laser based operations.…”

Benign Prostat Hiperplazisi

“…BPH, histolojik bir tanım olarak malign olmayan prostatik doku hiperplazisidir. Klinik ve pratik açıdan bakıldığında prostat dokusundaki benign hiperplaziye sekonder alt üriner sistem disfonksiyonu olarak tanımlanmaktadır [1]. BPH klinik bir sendrom olup alt üriner sistem semptomları, mesane çıkış obstrüksiyonu ve benign prostatik büyüme şeklinde 3 komponenti bulunmaktadır [2].…”

Venlafaxine-induced prostatism: a case report

“…By the age of 50 years, about 50% of men are identified with prostatism symptoms; by 80 years, 90% of men are identified [2,3]. Prostatism may develop some complications including recurrent urinary tract infections, hematuria and renal failure [4].…”